An Integrated Circulating Biomarker Index for Overall Survival in Metastatic Breast Cancer Treated with Chemotherapy: A Retrospective Cohort Study.

Background Circulating biomarkers associated with tumor–immune interactions and clinical outcomes in breast cancer are generally evaluated individually. We investigated their prognostic significance in patients with metastatic breast cancer (MBC) receiving chemotherapy and developed an integrated biomarker index for overall survival (OS). Methods We retrospectively analyzed 43 patients with MBC who were receiving chemotherapy. Baseline circulating levels of tumor necrosis factor-α (TNF-α), soluble interleukin-2 receptor (sIL-2R), interleukin-6 (IL-6), IL-8, transforming growth factor-β (TGF-β), and thymidine kinase 1 (TK1) were measured. Biomarkers associated with OS were combined to construct the OS Integrated Biomarker Index (OS-IBI). Associations of the OS-IBI with survival and peripheral immune and inflammatory parameters were evaluated. Results In univariable Cox proportional hazards analysis, TNF-α ( p = 0.008), sIL-2R ( p < 0.001), IL-6 ( p = 0.001), and TK1 ( p = 0.003) were significantly associated with shorter OS and were subsequently incorporated into the OS-IBI. The OS-IBI showed numerically greater discrimination for OS than any individual biomarker (AUC 0.801, 95% CI: 0.658–0.944) and remained independently associated with shorter OS in multivariable analysis (HR 1.82, 95% CI: 1.31–2.53; p < 0.001). Bootstrap internal validation yielded an optimism-corrected C-index of 0.817. Higher OS-IBI values were associated with lower proportions of CD4 + lymphocytes and higher proportions of myeloid-derived suppressor cells, as well as unfavorable systemic inflammatory parameters. Conclusions The OS-IBI, integrating circulating biomarkers related to inflammation, immune activation, and tumor proliferation, was independently associated with OS and with peripheral features of systemic immune dysregulation. These findings warrant validation in larger, independent cohorts.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11532914/v1
Primary Topic
Breast Cancer Treatment Studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

An Integrated Circulating Biomarker Index for Overall Survival in Metastatic Breast Cancer Treated with Chemotherapy: A Retrospective Cohort Study.

Ayumu Mitsuyoshi, Masafumi Shimoda, Sayaka Urano, Miki Komatsu et al.
Research Square
Breast Cancer Treatment Studies
preprint

An Integrated Circulating Biomarker Index for Overall Survival in Metastatic Breast Cancer Treated with Chemotherapy: A Retrospective Cohort Study.

Ayumu Mitsuyoshi, Masafumi Shimoda, Sayaka Urano, Miki Komatsu, Tomoko Higuchi, Akira Hattori, Toshifumi Wakai, Arisa Nishimukai, Haruka Kanaoka, Yasuo Miyoshi, Masayuki Nagahashi, Junko Tsuchida, Aoi Oshiro, Yusa Togashi, Mamiko Kuroiwa, Gen Sugimoto, S. Yoshida
preprint en

Abstract

Background Circulating biomarkers associated with tumor–immune interactions and clinical outcomes in breast cancer are generally evaluated individually. We investigated their prognostic significance in patients with metastatic breast cancer (MBC) receiving chemotherapy and developed an integrated biomarker index for overall survival (OS). Methods We retrospectively analyzed 43 patients with MBC who were receiving chemotherapy. Baseline circulating levels of tumor necrosis factor-α (TNF-α), soluble interleukin-2 receptor (sIL-2R), interleukin-6 (IL-6), IL-8, transforming growth factor-β (TGF-β), and thymidine kinase 1 (TK1) were measured. Biomarkers associated with OS were combined to construct the OS Integrated Biomarker Index (OS-IBI). Associations of the OS-IBI with survival and peripheral immune and inflammatory parameters were evaluated. Results In univariable Cox proportional hazards analysis, TNF-α ( p = 0.008), sIL-2R ( p < 0.001), IL-6 ( p = 0.001), and TK1 ( p = 0.003) were significantly associated with shorter OS and were subsequently incorporated into the OS-IBI. The OS-IBI showed numerically greater discrimination for OS than any individual biomarker (AUC 0.801, 95% CI: 0.658–0.944) and remained independently associated with shorter OS in multivariable analysis (HR 1.82, 95% CI: 1.31–2.53; p < 0.001). Bootstrap internal validation yielded an optimism-corrected C-index of 0.817. Higher OS-IBI values were associated with lower proportions of CD4 + lymphocytes and higher proportions of myeloid-derived suppressor cells, as well as unfavorable systemic inflammatory parameters. Conclusions The OS-IBI, integrating circulating biomarkers related to inflammation, immune activation, and tumor proliferation, was independently associated with OS and with peripheral features of systemic immune dysregulation. These findings warrant validation in larger, independent cohorts.

Research Square
Hyogo Medical University (JP), Niigata University (JP)
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon